1. Field of the Invention
The invention relates to a closure system for blood vessel punctures, and more particularly, the invention relates to a system and method for facilitating hemostasis of blood vessel punctures with an absorbable sponge material.
2. Brief Description of the Related Art
A large number of diagnostic and interventional procedures involve the percutaneous introduction of instrumentation into a vein or artery. For example, coronary angioplasty, angiography, atherectomy, stenting of arteries, and many other procedures often involve accessing the vasculature through a catheter placed in the femoral artery or other blood vessel. Once the procedure is completed and the catheter or other instrumentation is removed, bleeding from the punctured artery must be controlled.
Traditionally, external pressure is applied to the skin entry site to stem bleeding from a puncture wound in a blood vessel. Pressure is continued until hemostasis has occurred at the puncture site. In some instances, pressure must be applied for a up to an hour or more during which time the patient is uncomfortably immobilized. In addition, a risk of hematoma exists since bleeding from the vessel may continue beneath the skin until sufficient clotting effects hemostasis. Further, external pressure to close the vascular puncture site works best when the vessel is close to the skin surface and may be unsuitable for patients with substantial amounts of subcutaneous adipose tissue since the skin surface may be a considerable distance from the vascular puncture site.
More recently, devices have been proposed to promote hemostasis directly at a site of a vascular puncture. One class of such puncture sealing devices features an intraluminal anchor which is placed within the blood vessel and seals against an inside surface of the vessel puncture. The intraluminal plug may be used in combination with a sealing material positioned on the outside of the blood vessel, such as collagen. Sealing devices of this type are disclosed in U.S. Pat. Nos. 4,852,568; 4,890,612; 5,021,059; and 5,061,274.
Another approach to subcutaneous blood vessel puncture closure involves the delivery of non-absorbable tissue adhesives, such cyanoacrylate, to the perforation site. Such a system is disclosed in U.S. Pat. No. 5,383,899.
The application of an absorbable material such as collagen or a non-absorbable tissue adhesive at the puncture site has several drawbacks including: 1) possible injection of the material into the blood vessel causing thrombosis; 2) a lack of pressure directly on the blood vessel puncture which may allow blood to escape beneath the material plug into the surrounding tissue; and 3) the inability to accurately place the absorbable material plug directly over the puncture site.
The use of an anchor and plug system addresses these problems to some extent but provides other problems including: 1) complex and difficult application; 2) partial occlusion of the blood vessel by the anchor when placed properly; and 3) complete blockage of the blood vessel or a branch of the blood vessel by the anchor if placed improperly. Another problem with the anchor and plug system involves reaccess. Reaccess of a particular blood vessel site sealed with an anchor and plug system is not possible until the anchor has been completely absorbed because the anchor could be dislodged into the blood stream by an attempt to reaccess.
Yet another approach to subcutaneous puncture closure involves the internal suturing of the blood vessel puncture with a specially designed suturing device. However, these suturing devices involve a significant number of steps to perform suturing and require substantial expertise.
Accordingly, it would be desirable to provide a system for facilitating hemostasis of blood vessel punctures which addresses the drawbacks of the known systems.
One aspect of the present invention relates to a device for facilitating hemostasis of a puncture in the wall of a blood vessel including an introducer for hydrating and compressing an absorbable sponge pledget for delivery to a patient to facilitate hemostasis of the puncture and a plunger insertable into the introducer for ejection of the pledget from the introducer into a patient to seal the puncture in the blood vessel wall. The introducer includes a staging chamber with a first diameter configured to receive the absorbable sponge pledget, a delivery chamber with a second diameter smaller than the first diameter, and a tapered section between the staging chamber and the delivery chamber for compressing the pledget.
In accordance with another aspect of the present invention, a system for facilitating hemostasis of a puncture in the wall of a blood vessel includes a tract dilator, an introducer, and a plunger each having a lumen for allowing the tract dilator, introducer, and plunger to be passed over a guidewire. The introducer lumen includes a staging chamber configured to receive an absorbable sponge pledget and a delivery chamber. The plunger is insertable into the introducer for ejection of the pledget from the delivery chamber into a patient to facilitate hemostasis of a puncture in a blood vessel wall.
In accordance with an additional aspect of the present invention, a method for facilitating hemostasis of a puncture in the wall of a blood vessel includes the steps of: establishing a depth of a blood vessel puncture from the skin of a patient; loading an introducer with an absorbable sponge pledget by hydrating and compressing the pledget; loading the introducer over a guidewire positioned in the blood vessel by inserting the guidewire through the hydrated and compressed pledget; and ejecting the pledget adjacent the blood vessel puncture to facilitate hemostasis of the puncture while maintaining the guidewire in place.
The invention will now be described in greater detail with reference to the preferred embodiments illustrated in the accompanying drawings, in which like elements bear like reference numerals, and wherein:
An over the wire delivery system delivers an absorbable sponge pledget in a hydrated condition to a blood vessel puncture site to achieve hemostasis. The over the wire delivery system includes a tract dilator 10, an introducer 12, and a pusher 14, illustrated in kit form in
Prior to discussing the present invention in further detail, the following terms are defined:
“Pledget” means a piece of absorbable sponge formed into a generally elongated shape having a size which allows delivery in a hydrated state through a delivery cannula, or introducer to a site of a puncture in a blood vessel.
“Absorbable sponge” means a biocompatible material which is capable of being hydrated, is resiliently compressible in a hydrated state, and when implanted within a human or other mammalian body is absorbed by the body. Preferably the absorbable sponge is non-immunogenic.
“Hydrate” means to partially or fully saturate with a fluid, such as, saline, water, contrast agent, thrombin, therapeutic agents, or the like.
“Kneading” of the absorbable sponge material means both dry and wet manipulation of sponge material which compresses, enlarges, or changes the shape of the sponge material causing the sponge material to have improved expansion response.
As shown in
A depth indicator 30 is positioned around the tract dilator 10 and is movable in an axial direction. Once the tract dilator has been inserted until the distal tip 20 abuts the external wall of the blood vessel 102, as shown in
A side view of an introducer 12 is illustrated in
The absorbable sponge pledget 40 according to one preferred embodiment of the invention is formed from a sheet of absorbable sponge material which has been cut into a rectangular shape and rolled to form a compact, substantially cylindrical, elongated pledget. The pledget 40 is sized to be received within the staging chamber 34 of the introducer 12 in a dry rolled state.
Once the pledget 40 has been inserted into the staging chamber 34 of the introducer 12, a conventional syringe 50 containing a hydrating fluid is connected to the luer fitting 42, as shown in
As an alternative to placement of a finger at the distal end of the introducer 12 during advancement of the pledget 40 into the delivery chamber, a removable cap may be used. Further, the vent holes 46 may be omitted and a screen or a cap having a screen may be used to allow fluid to pass through the screen while the screen prevents the pledget 40 from being ejected.
The introducer 12 also includes a depth indicator 52 which is an axially movable member used to indicate the depth to which the introducer should be inserted into the patient to achieve the proper positioning of the pledget 40 at the puncture site. The depth indicator 52 of the introducer 12 is aligned with the depth indicator 30 on the tract dilator 10 to achieve proper pledget delivery positioning.
The introducer 12 may be formed in any known manner such as by injection molding from a plastic material. Preferably, the introducer 12 is transparent so that the pledget 40 can be viewed through the introducer and the user can visually confirm the pledget position. The introducer lumen may be provided with a reducing coating for improved pledget delivery. The delivery fluid also reduces friction for improved delivery by wetting the exterior surface of the pledget.
The pusher 14, as illustrated in
The pusher 14 also may include a fitting 58 for connecting the proximal end of the pusher to the proximal end of the introducer 12. The fitting 58 acts as a stop to limit the motion of the pusher 14 with respect to the introducer 12. A female luer fitting 60 may also be included at the proximal end of the pusher 14 for connection of a syringe to the pusher for injection of beneficial agent through the pusher.
A method of delivering an absorbable sponge pledget 40 to facilitate hemostasis of a blood vessel puncture wound will now be described with respect to the steps illustrated in
A sheet of absorbable sponge material is cut into a rectangle, is rolled tightly to form a pledget 40, and is placed into the staging chamber 34 of the introducer 12. The steps of cutting and rolling the pledget 40 and placing the dry pledget in the introducer staging chamber 34 may be performed before or after the intervascular procedure. Alternatively, the introducer 12 may be provided preloaded with a prepared pledget 40. With the pledget 40 placed in the introducer, the syringe 50 is filled with a hydrating fluid such as saline, thrombin, contrast agent, other therapeutic agent, or the like and attached to the introducer 12 as illustrated in
As shown in
As shown in
After feeding the guidewire 26 through the introducer, the guidewire 26 is fed through the pusher 14 and the pusher is advanced into the introducer until the distal end 56 of the pusher is in contact with the pledget 40. The introducer 12 and pusher 14 are then advanced together down though the skin 106 and the subcutaneous tissue 104 until the depth indicator 52 on the exterior of the introducer is at the skin level.
In the step illustrated in
One type of absorbable sponge material which is acceptable for use in the present invention is Gelfoam, manufactured by the Upjohn Company. Gelfoam is a porous, pliable, cross-linked gelatin material and is available commercially in sheet form as pre-compressed or non-compressed sponge. The material may be provided preformed as a pledget 40 or may be cut with a punch or a stencil and knife and rolled to form a pledget as described above. Once hydrated, the pledget 40 can be easily compressed to fit into a lumen having a smaller cross sectional area than the original cross sectional area of the pledget. Additionally, the kneading of the hydrated pledget 40 during delivery encourages air trapped within the Gelfoam to be expelled and replaced with fluid, allowing rapid expansion upon delivery. When a pledget 40 of a pre-compressed Gelfoam is hydrated and kneaded (expelling air) during delivery, the pledget will have the absorption capacity to rapidly expand to many times (e.g., 3 or more times) its original dry volume upon delivery. When a pledget 40 of the non-compressed Gelfoam is hydrated and kneaded (expelling air) during delivery, the pledget will have the absorption capacity to rapidly expand to its original dry volume upon delivery. These properties make the Gelfoam sponge material particularly useful for facilitating hemostasis of puncture wounds by injection.
Abrupt lumen diameter changes within the introducer 12, such as at the tapered section 38, will improve “kneading” of the absorbable sponge material passing through the introducer. Manipulation of the dry absorbable sponge material, such as the rolling of the pledget 40, also provides kneading. Kneading improves hydration of the sponge material thereby improving the expansion properties of the hydrated delivered absorbable sponge.
According to alternative embodiments of the introducer, enlarged, recessed, or irregular areas in the lumen of the introducer are provided to impart additional kneading action to the absorbable sponge material further improving expansion properties of the sponge.
Another alternative embodiment for improved kneading of the pledget 40 includes features on the guidewire, such as, irregularities, curves, bends, or the like. The guidewire kneading features will improve kneading of the pledget 40 as the guidewire 26 is inserted through the pledget.
The embodiment of
The barbs 66 help to hold the pledget 40 in place as the guidewire 26 is inserted through the pledget. This is particularly useful when using a conventional coiled guidewire which creates a significant amount of friction when threaded through the absorbable sponge material. Alternatively, a plastic sheathed guidewire or hydrophilically coated guidewire can be used which is more easily threaded through the absorbable sponge material. A guidewire with a reduced diameter proximal portion will also facilitate threading of the guidewire 26 through the pledget 40.
As an alternative to the barbs 66 or a specially designed guidewire, the plunger 14 can be used to hold the pledget 40 in place during threading of the guidewire 26 through the pledget. A hydraulic back pressure can also be created to hold the pledget 40 in place by blocking the proximal end of the introducer 12, such as by the user's finger. Such a hydraulic back pressure will help to hold the pledget in place in the delivery chamber.
Although the use of a tract dilator 10 has been described above, the introducer 12 can be used in place of the dilator and the depth determining step can be performed while inserting the introducer, particularly where a plastic sheathed guidewire, other friction reducing guidewire, or other friction reducing feature is used.
Among other advantages this invention permits the delivery of more absorbable sponge material down a smaller tract by hydrating and compressing the absorbable sponge material. The over the wire delivery method ensures that the absorbable sponge pledget 40 is delivered directly over the puncture site and remains in the proper position while hemostasis is achieved. The vessel depth indicator system ensures that the absorbable sponge material is positioned adjacent the exterior of the blood vessel and does not extend into the blood vessel to possibly induce thrombosis. The kneading of the absorbable sponge material during rolling of the dry sponge and while hydrated and passing through the introducer improves the expansion properties of the sponge material.
The absorbable sponge material can be absorbed by the body in a period of time between several days and several months depending on the absorbable sponge material used. A pledget 40 formed of commercially available Gelfoam material will be absorbed by the body within 1 to 6 weeks. However, the pledget material may be engineered to provide different rates of absorption. For example, Gelfoam can be designed to be absorbed at different rates by varying the degree of cross-linking. Preferably, the pledget 40 is designed to be absorbed in less than one month.
Although the pledget 40 has been described as formed from a rectangular shaped piece of an absorbable sponge material which is rolled into a cylindrical shape, the pledget may also be formed in different shapes. For example, the pledget 40 may be preformed in a variety of cross sections including circular, rectangular, star, or other multi-sided shape. The pledget 40 may have a folded cross section and may have through or blind holes formed in the dry pledget. In addition, the pledget size and shape can be matched to the size and shape of a particular delivery site.
The continuous structure of the delivered absorbable sponge pledget 40 provides more secure and reliable placement of a plug of material against the blood vessel puncture than a paste or liquid. The continuous sponge structure can even facilitate partial withdrawal, removal, or movement of the ejected pledget. In accordance with one aspect of the invention, the absorbable sponge material can be hydrated with a clotting agent such as thrombin, a contrast agent, another beneficial agent, a combination of fluids, or the like.
The absorbable sponge pledget 40 may be presoaked with a beneficial agent such as thrombin for delivery of the beneficial agent to the punctured blood vessel. Alternatively, the pledget 40 may be hydrated with a beneficial liquid agent used as the hydrating fluid within the syringe 50. Further, the beneficial agent may be delivered to the pledget 40 after the pledget is ejected at the blood vessel puncture site through the lumen of the pusher 14 or through the introducer 12.
The treatment of a blood vessel puncture with a hydrated and injected pledget 40 of absorbable sponge to facilitate hemostasis provides substantial advantages in comfort over external pressure methods. In addition, the present invention also provides advantages over the insertion of a absorbable sponge material in a dry state or injection of a liquid or paste. In particular, the hydration and manipulation or “kneading” of the hydrated Gelfoam pledget 40 as it is passed through the introducer 12 improves the expansion and absorption characteristics of the Gelfoam. The injected Gelfoam conforms in shape quickly to the shape of the puncture site and immediately begins blocking blood flow through the puncture site and providing local compression. In contrast, a dry piece of sponge material does not swell until the blood has sufficiently saturated the sponge material, which can take up to hours. The hydrated and kneaded sponge material will expand to a larger size much more quickly when wetted than a piece of dry sponge material when wetted.
Because the amount of subcutaneous fat and tissue between the skin 106 and the blood vessel 102 varies between patients from approximately 0.5 cm to 15 cm or more the system may be provided in different lengths for use in different patients. The pledget 40 size and shape may also be varied for different patients. The absorbable sponge material should form a complete plug over the puncture site without expanding into the blood vessel or exiting the skin of the patient. In some instances where the amount of subcutaneous tissue is great it may be desirable to deliver multiple pledgets 40 in spaced apart positions along the tract leading to the puncture site.
The particular size and shape of the introducer 12 may vary depending on the size of the access site, amount of subcutaneous tissue, and the size of pledget 40 to be delivered. According to one example of the present invention, a pledget 40 is formed from a rectangular piece of pre-compressed Gelfoam approximately 2 by 3 cm with a thickness of 0.15 cm. The Gelfoam is rolled or folded into a pledget having a length of approximately 3 cm. An introducer 12 for delivery of this pledget to a patient with an average amount of subcutaneous tissue has a staging chamber length of about 2.5 to 6 cm, preferably approximately 3 cm, a staging chamber inner diameter of about 0.12 to 1.5 cm, preferably approximately 0.4 cm, and a delivery chamber 36 which is typically longer than the staging chamber and has an inner diameter smaller than that of the staging chamber of about 1 cm or less, preferably approximately 0.33 cm or less. The particular length of the delivery chamber 36 depends on both the subcutaneous tissue depth of the patient and the linear expansion of the pledget 40 as it moves from the staging chamber 34 to the delivery chamber. An angle made by a wall of the tapered section 38 with a longitudinal axis of the adaptor 12 may vary from about 5° to 90°, but is preferably between about 30° and 60°, more preferably approximately 45°. The tapered section 38 is illustrated with a substantially planar interior surface, when shown in cross section. However, the tapered section 38 may also have a convex or concave surface in cross-section. This example of pledget 40 and introducer 12 configurations is merely exemplary of the present invention.
In accordance with an alternative embodiment of the invention, the pledget 40 may be provided with a rapidly dissolvable tip extending from a distal end of the pledget. Examples of rapidly absorbable or dissolvable tip materials include water-soluble, biocompatible, non-toxic, and preferably non-immunogenic polymers such as poly vinyl alcohol (PVA) and ploy vinyl pyrrolidone (PVP). Other examples could include gelatin derived from porcine or bovine sources. Still other possible tip materials could include, but are not limited to, poly lactic-glycolic acid, poly (proline), ploy (ethylene oxide) and carbowaxes, methyl cellulose, carboxymethyl cellulose, poly (acrylic acid), poly (hydroxyethyl methacrylate), poly (acrylamide), natural plant gums, and poly (methyl vinyl ether-maleic anhydride). The rapidly dissolvable tip is arranged to extend slightly into the blood vessel and will provide an additional locating mechanism which will hold the pledget at the proper position over the puncture after the guidewire is removed in the step illustrated in
While the invention has been described in detail with reference to the preferred embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made and equivalents employed, without departing from the present invention.
This application is a divisional, of application Ser. No. 09/071,284, filed May 1, 1998 now U.S. Pat. No. 6,162,192.
Number | Name | Date | Kind |
---|---|---|---|
581235 | Kenyon | Apr 1897 | A |
1578517 | Hein | Mar 1926 | A |
2086580 | Shirley | Jul 1937 | A |
2370319 | Lippincott | Feb 1945 | A |
2465357 | Correll | Mar 1949 | A |
2492458 | Bering, Jr. | Dec 1949 | A |
2507244 | Correll | May 1950 | A |
2558395 | Studer | Jun 1951 | A |
2597011 | MacMasters et al. | May 1952 | A |
2680442 | Linzmayer | Jun 1954 | A |
2761446 | Reed | Sep 1956 | A |
2814294 | Figge | Nov 1957 | A |
2824092 | Thompson | Feb 1958 | A |
2874776 | Hooe | Feb 1959 | A |
2899362 | Sieger, Jr. et al. | Aug 1959 | A |
2997195 | Chuen Yuen | Aug 1961 | A |
3157524 | Artandi | Nov 1964 | A |
3358689 | Higgins | Dec 1967 | A |
3411505 | Nobis | Nov 1968 | A |
3703174 | Smith | Nov 1972 | A |
3724465 | Duchane | Apr 1973 | A |
3736939 | Taylor | Jun 1973 | A |
4000741 | Binard et al. | Jan 1977 | A |
4098728 | Rosenblatt | Jul 1978 | A |
4211323 | Olsen | Jul 1980 | A |
4218155 | Weidner | Aug 1980 | A |
4219026 | Layton | Aug 1980 | A |
4224945 | Cohen | Sep 1980 | A |
4238480 | Sawyer | Dec 1980 | A |
4292972 | Pawelchak | Oct 1981 | A |
4323072 | Rosenbluth et al. | Apr 1982 | A |
4340066 | Shah | Jul 1982 | A |
4390018 | Zulowski | Jun 1983 | A |
4404970 | Sawyer | Sep 1983 | A |
4405314 | Cope | Sep 1983 | A |
4515637 | Cioca | May 1985 | A |
4573573 | Favaro | Mar 1986 | A |
4573576 | Krol | Mar 1986 | A |
4587969 | Gillis | May 1986 | A |
4588395 | Lemelson | May 1986 | A |
4591094 | Morris | May 1986 | A |
4619261 | Guerrero | Oct 1986 | A |
4619913 | Luck et al. | Oct 1986 | A |
4644649 | Seaman et al. | Feb 1987 | A |
4645488 | Matukas | Feb 1987 | A |
4699616 | Norwak | Oct 1987 | A |
4708718 | Daniels | Nov 1987 | A |
4744364 | Kensey | May 1988 | A |
4790819 | Li et al. | Dec 1988 | A |
4829994 | Kurth | May 1989 | A |
4832688 | Sagae et al. | May 1989 | A |
4836204 | Landymore et al. | Jun 1989 | A |
4839204 | Yoshino | Jun 1989 | A |
4850960 | Grayzel | Jul 1989 | A |
4852568 | Kensey | Aug 1989 | A |
4869143 | Merrick | Sep 1989 | A |
4890612 | Kensey | Jan 1990 | A |
4900303 | Lemelson | Feb 1990 | A |
4929246 | Sinofsky | May 1990 | A |
4936835 | Haaga | Jun 1990 | A |
4950234 | Fujioka et al. | Aug 1990 | A |
5007895 | Burnett | Apr 1991 | A |
5021059 | Kensey et al. | Jun 1991 | A |
5049138 | Chevalier et al. | Sep 1991 | A |
5053046 | Janese | Oct 1991 | A |
5061274 | Kensey | Oct 1991 | A |
5080655 | Haaga | Jan 1992 | A |
5106376 | Monenen et al. | Apr 1992 | A |
5108421 | Fowler | Apr 1992 | A |
5129889 | Hahn | Jul 1992 | A |
5160323 | Andrew | Nov 1992 | A |
5163904 | Lampropoulous et al. | Nov 1992 | A |
5167624 | Butler et al. | Dec 1992 | A |
5192290 | Hilgal | Mar 1993 | A |
5192300 | Fowler | Mar 1993 | A |
5192301 | Kamiya et al. | Mar 1993 | A |
5195988 | Haaga | Mar 1993 | A |
5219899 | Panster et al. | Jun 1993 | A |
5220926 | Jones | Jun 1993 | A |
5221259 | Weldon et al. | Jun 1993 | A |
5222974 | Kensey et al. | Jun 1993 | A |
5232453 | Plass et al. | Aug 1993 | A |
5242683 | Klaveness | Sep 1993 | A |
5254105 | Haaga | Oct 1993 | A |
5275616 | Fowler | Jan 1994 | A |
5282827 | Kensey et al. | Feb 1994 | A |
5292309 | Van Tassel et al. | Mar 1994 | A |
5299581 | Donnell et al. | Apr 1994 | A |
5310407 | Casale | May 1994 | A |
5320639 | Rudnick | Jun 1994 | A |
5322515 | Karas et al. | Jun 1994 | A |
5325857 | Nabai et al. | Jul 1994 | A |
5334216 | Vidal et al. | Aug 1994 | A |
5342388 | Toller | Aug 1994 | A |
5350399 | Erlebacher et al. | Sep 1994 | A |
5352211 | Merskelly | Oct 1994 | A |
5366480 | Corriveau et al. | Nov 1994 | A |
5370656 | Shevel | Dec 1994 | A |
5383896 | Gershony et al. | Jan 1995 | A |
5383899 | Hammerslag | Jan 1995 | A |
5385550 | Su et al. | Jan 1995 | A |
5388588 | Nabai et al. | Feb 1995 | A |
5391183 | Janzen et al. | Feb 1995 | A |
5395353 | Scribner | Mar 1995 | A |
5399361 | Song et al. | Mar 1995 | A |
5417699 | Klein et al. | May 1995 | A |
5419765 | Weldon et al. | May 1995 | A |
5431639 | Shaw | Jul 1995 | A |
5437292 | Kipshidze et al. | Aug 1995 | A |
5437631 | Janzen | Aug 1995 | A |
5441517 | Kenesey et al. | Aug 1995 | A |
5447502 | Haaga | Sep 1995 | A |
5458570 | May, Jr. | Oct 1995 | A |
5462194 | Barawell | Oct 1995 | A |
5467780 | Nabai et al. | Nov 1995 | A |
5478352 | Fowler | Dec 1995 | A |
5479936 | Nabai et al. | Jan 1996 | A |
5486195 | Myers et al. | Jan 1996 | A |
5490736 | Haber et al. | Feb 1996 | A |
5507279 | Fortune | Apr 1996 | A |
5522840 | Krajicek | Jun 1996 | A |
5522850 | Yomtov et al. | Jun 1996 | A |
5526822 | Burbank et al. | Jun 1996 | A |
5529577 | Hammerslag | Jun 1996 | A |
5540715 | Katsaros et al. | Jul 1996 | A |
5542914 | Van Iten | Aug 1996 | A |
5545175 | Abidin et al. | Aug 1996 | A |
5545178 | Kensey et al. | Aug 1996 | A |
5554108 | Browning et al. | Sep 1996 | A |
5558853 | Quay | Sep 1996 | A |
5571168 | Toro | Nov 1996 | A |
5591204 | Janzen et al. | Jan 1997 | A |
5591205 | Fowler | Jan 1997 | A |
5601207 | Paczonay | Feb 1997 | A |
5601601 | Tal et al. | Feb 1997 | A |
5601602 | Fowler | Feb 1997 | A |
5601603 | Illi | Feb 1997 | A |
5620461 | Muijs Van De Moer | Apr 1997 | A |
5624685 | Takahashi et al. | Apr 1997 | A |
5645566 | Brenneman et al. | Jul 1997 | A |
5645849 | Pruss et al. | Jul 1997 | A |
5649547 | Ritchart et al. | Jul 1997 | A |
5653730 | Hammerslag | Aug 1997 | A |
5665107 | Hammerslag | Sep 1997 | A |
5674346 | Kundel | Oct 1997 | A |
5676689 | Kensey et al. | Oct 1997 | A |
5681279 | Roper et al. | Oct 1997 | A |
5707393 | Kensey et al. | Jan 1998 | A |
5716375 | Fowler | Feb 1998 | A |
5725498 | Janzen et al. | Mar 1998 | A |
5741223 | Janzen et al. | Apr 1998 | A |
5769086 | Ritchart et al. | Jun 1998 | A |
5775333 | Burbank et al. | Jul 1998 | A |
5782861 | Cragg et al. | Jul 1998 | A |
5800389 | Burney et al. | Sep 1998 | A |
5810806 | Ritchart et al. | Sep 1998 | A |
5827218 | Nguyen et al. | Oct 1998 | A |
5830130 | Janzen et al. | Nov 1998 | A |
5858008 | Capaccio | Jan 1999 | A |
5861004 | Kensey et al. | Jan 1999 | A |
5868762 | Cragg et al. | Feb 1999 | A |
5902310 | Foerster et al. | May 1999 | A |
5931165 | Reich et al. | Aug 1999 | A |
5984950 | Cragg et al. | Nov 1999 | A |
6007563 | Nash et al. | Dec 1999 | A |
6027471 | Fallon et al. | Feb 2000 | A |
6027482 | Imbert | Feb 2000 | A |
6033427 | Lee | Mar 2000 | A |
6056768 | Cates et al. | May 2000 | A |
6063061 | Wallace et al. | May 2000 | A |
6063085 | Tay et al. | May 2000 | A |
6066325 | Wallace et al. | May 2000 | A |
6071300 | Brenneman et al. | Jun 2000 | A |
6071301 | Cragg et al. | Jun 2000 | A |
6086607 | Cragg et al. | Jul 2000 | A |
6090130 | Nash et al. | Jul 2000 | A |
6126675 | Shchervinsky et al. | Oct 2000 | A |
6161034 | Burbank et al. | Dec 2000 | A |
6162192 | Cragg et al. | Dec 2000 | A |
6183497 | Sing et al. | Feb 2001 | B1 |
6197327 | Harrison et al. | Mar 2001 | B1 |
6200328 | Cragg et al. | Mar 2001 | B1 |
6315753 | Cragg | Nov 2001 | B1 |
6325789 | Janzen et al. | Dec 2001 | B1 |
6371974 | Brenneman et al. | Apr 2002 | B1 |
6440151 | Cragg et al. | Aug 2002 | B1 |
6440153 | Cragg et al. | Aug 2002 | B1 |
6447534 | Cragg et al. | Sep 2002 | B1 |
6503222 | Lo | Jan 2003 | B1 |
6527734 | Cragg et al. | Mar 2003 | B1 |
6540735 | Ashby et al. | Apr 2003 | B1 |
6544236 | Cragg et al. | Apr 2003 | B1 |
6547806 | Ding | Apr 2003 | B1 |
6585680 | Bugge | Jul 2003 | B1 |
6610026 | Cragg et al. | Aug 2003 | B1 |
20020002889 | Ashby et al. | Jan 2002 | A1 |
20020016612 | Ashby et al. | Feb 2002 | A1 |
20020038133 | Sing et al. | Mar 2002 | A1 |
20020042378 | Reich et al. | Apr 2002 | A1 |
20020062104 | Ashby et al. | May 2002 | A1 |
20020156495 | Brenneman et al. | Oct 2002 | A1 |
20030028140 | Greff et al. | Feb 2003 | A1 |
20030088269 | Ashby | May 2003 | A1 |
20030088271 | Cragg et al. | May 2003 | A1 |
20030120258 | Ashby et al. | Jun 2003 | A1 |
20030135237 | Cragg et al. | Jul 2003 | A1 |
20040019328 | Sing et al. | Jan 2004 | A1 |
20040019330 | Ashby | Jan 2004 | A1 |
Number | Date | Country |
---|---|---|
32826 | Jul 1981 | EP |
476178 | Mar 1992 | EP |
482350 | Apr 1992 | EP |
0557963 | Feb 1993 | EP |
0637432 | Sep 1994 | EP |
0637431 | Nov 1994 | EP |
2641692 | Jan 1990 | FR |
1509023 | Apr 1978 | GB |
1569660 | Jun 1980 | GB |
782814 | Nov 1980 | RU |
1088709 | Apr 1984 | RU |
WO 9112847 | Sep 1991 | WO |
WO 9402072 | Mar 1994 | WO |
WO 9428800 | Dec 1994 | WO |
WO 9528124 | Oct 1995 | WO |
WO 9532669 | Dec 1995 | WO |
WO 9532671 | Dec 1995 | WO |
WO 9532679 | Dec 1995 | WO |
WO 9608208 | Mar 1996 | WO |
WO 9624290 | Aug 1996 | WO |
WO 9707934 | Mar 1997 | WO |
WO 9806346 | Feb 1998 | WO |
WO 9966834 | Dec 1999 | WO |
WO 0493649 | Nov 2004 | WO |
Number | Date | Country | |
---|---|---|---|
Parent | 09071284 | May 1998 | US |
Child | 09613439 | US |